51. 全身性強皮症 ［臨床試験数：466，薬物数：536（DrugBank：142），標的遺伝子数：110，標的パスウェイ数：210］
Searched query = "Scleroderma", "Systemic sclerosis", "SSc", "dcSSc", "lcSSc"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
|1||JPRN-jRCTc071190041||04/01/2019||09/01/2020||A clinical trial of autologous stem cell transplantation for severe systemic sclerosis||A single-arm, open-label, phase 2 study of autologous CD34+ stem cells-selected transplantation for severe systemic sclerosis - A single-arm, open-label, phase 2 study of autologous CD34+ stem cells-selected transplantation for severe systemic sclerosis||systemic sclerosis||After peripheral blood stem cell mobilization and aphereisi with cyclophosphamide 4 g/m2 and G-CSF, CD34+ cells were enriched by using anti-CD34 immunomagnetic beads. Conditioning was performed using high-dose cyclophosphamide (50 mg/kg) for 4 days, and freeze-thawed CD34+ cells were transplanted.||Akashi Koichi||NULL||Recruiting||>= 16age old||< 65age old||Both||12||Phase 2||Japan|
|2||NCT03593902||May 17, 2018||28/6/2018||Cardiac Safe Transplants for Systemic Sclerosis||Autologous Hematopoietic Stem Cell Transplant for Patients With Systemic Sclerosis and Cardiac Dysfunction||Systemic Sclerosis;Scleroderma||Drug: Rituximab;Drug: Fludarabine;Drug: Cyclophosphamide;Drug: Mesna;Drug: rATG;Drug: Methylprednisolone;Drug: G-CSF;Biological: IVIg;Biological: Autologous Stem Cells||Northwestern University||NULL||Terminated||18 Years||65 Years||All||9||Phase 2/Phase 3||United States|
|3||NCT00058578||June 1999||8/4/2003||Stem Cell Transplant to Treat Patients With Systemic Sclerosis||Autologous T-Cell Depleted Peripheral Blood Stem Cell Transplantation for the Treatment of Selected Patients With Systemic Sclerosis||Systemic Sclerosis||Drug: Cyclophosphamide;Drug: Mesna;Drug: G-CSF;Procedure: Leukopheresis;Procedure: Total Body Irradiation||Baylor College of Medicine||The Methodist Hospital System;Center for Cell and Gene Therapy, Baylor College of Medicine||Completed||18 Years||65 Years||All||24||Phase 1||United States|